Background: More than 3,000 multiple sclerosis (MS) patients were treated with disease-modifying drugs (DMDs) in the Region of Valencia during 2005-2014. We aimed at describing the demographic and clinical characteristics of MS patients who requested treatment with DMDs, variations in their use, and the factors associated with change to second-line therapies during this decade. Methods: A retrospective cohort study with information from Subcomité Especializado de Medicamentos de Alto Impacto Sanitario y/o Económico registers. A statistical analysis was run in 2 phases: descriptive analysis of the sample using classical statistical methods, and of DMD trend by a chi-square test for linear trends; analytic analysis to examine the factors associated with change to second-line treatment (logistic regression model). Results: We selected 2,205 patients (mean age 32.12, SD 9.64; 70% females, and 86.6% remising-remitting MS (RRMS)); 1,012 patients were attended to in highly specialized MS units (45.8%); 525 in monographic units (23.8%); and 668 in general units (30.2%). DMD prescriptions increased, and glatiramer acetate was more widespread at the end of the period (35.4%). Conclusion: Variability in access to different treatments was slight. The younger the patient, the higher the risk of first-line RRMS treatment failing in female gender and first treatment with interferon.

Keywords:
Natalizumab, Cohort study, Historical, Multiple sclerosis, Interferon-beta, Fingolimod, Glatiramer acetate
1.
Izquierdo Ayuso G: Esclerosis múltiple: impacto socioeconómico y en la calidad de vida de los pacientes. Med Clin (Barc) 2014;143 (suppl 3):7-12.
2.
López-Méndez P, Río J, Pérez-Ricart A, Tintoré M, Sastre-Garriga J, Cardona-Pascual I, et al: Adhesión terapéutica a tratamiento inmunomodulador de pacientes con esclerosis múltiple. Rev Neurol 2013;56:8-12.
3.
Ciccone A, Beretta S, Brusaferri F, Galea I, Protti A, Spreafico C: Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev 2008;1:CD006264.
4.
Vaquero García MD, Yecora Navarro MG: Uso terapéutico del interferón beta en el Insalud. Inf Ter Sist Nac Salud 2001;25:9-16.
5.
Agencia Española de Medicamentos y Productos Sanitarios: Fingolimod (Gilenya®): inicio de la revisión del balance beneficio-riesgo. 2012. www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2012/docs/NI-MUH_01-2012.pdf (accessed January 13, 2015).
6.
Cores EV, Vanotti S, Burin DI, Politis DG, Villa A: Factores asociados con la situación laboral de pacientes con esclerosis múltiple. Rev Neurol 2014;58:175-183.
7.
Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, et al: Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology 2011;77:355-363.
8.
Caja Calvo M, García del Busto Enguer N, López Tinoco MJ, Sánchez Alzaraz A: Ficha fingolimod. Eval Noved Ter Comunitat Valencia 2012;59:1-9.
9.
Conselleria de Sanitat. Resolución de la Secretaría Autonómica de la Agencia Valenciana de Salud de regulación del Programa de Medicamentos de Alto Impacto Sanitario y/o económico (PAISE). 2012. www.san.gva.es/documents/152919/157905/RESOL_PROG_MED_ALTOIMPACTOSANITARIO_ECONOMICO_PAISE.pdf (accessed January 13, 2015).
10.
Instituto Nacional de Estadística. 2016. http://www.ine.es/dynt3/inebase/index.html?padre=517 (accessed April 12, 2016).
11.
Bermejo Velasco PE, Blasco Quílez MR, Sánchez López AJ, García Merino A: Enfermedades desmielinizantes del sistema nervioso central. Concepto, clasificación y epidemiología. Medicine 2011;10:5065-5068.
12.
Compston A, Coles A: Multiple sclerosis. Lancet 2002;359:1221-1231.
13.
Confavreux C, Vukusic S: Age at disability milestones in multiple sclerosis. Brain 2006;129(pt 3):595-605.
14.
Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
15.
Gajofatto A, Calabrese M, Benedetti MD, Monaco S: Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers 2013;35:687-699.
16.
Oreja-Guevara C, Río J, Gobartt AL: En nombre del grupo de investigadores del estudio FUTURA. Cumplimiento de las guías de la Sociedad Española de Neurología en el tratamiento de los pacientes con esclerosis múltiple. Rev Neurol 2015;61:145-152.
17.
Fernández O, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernandez MC, Casanova-Estruch B, et al: Review of the novelties presented at the 28th congress of the European committee for treatment and research in multiple sclerosis (ECTRIMS) (I). Rev Neurol 2013;57:217-229.
18.
Fraile A, Tellez N, Neri MJ, Munoz MF, Fernandez-Herranz R: Change of treatment in patients with multiple sclerosis and its consequences in clinical practice. Rev Neurol 2012;54:415-419.
19.
Lindsey J, Scott T, Lynch S, Cofield S, Nelson F, Conwit R, et al: The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: design and baseline characteristics. Mult Scler Relat Disord 2012;1:81-86.
20.
Tremlett H, Zhao Y, Rieckmann P, Hutchinson M: New perspectives in the natural history of multiple sclerosis. Neurology 2010;74:2004-2015.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.